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doi:10.1016/j.jtcvs.2004.01.0141800 The Journal of Thoracic and CardBackground: We sought to (1) characterize the temporal pattern of T-cell panel
reactive antibody during ventricular assist device support, (2) identify predictors of
higher T-cell panel reactive antibody during ventricular assist device support, and
(3) determine whether device type remained a predictor after accounting for non-
random device selection.
Methods: Between December 1991 and August 2000, 239 patients received im-
plantable ventricular assist devices, of whom 231 had T-cell panel reactive antibody
measured. Panel reactive antibody was measured before implantation of the assist
device, approximately 2 weeks after device implantation, irregularly thereafter
depending on clinical events and length of support, and at transplantation. Longi-
tudinal mixed modeling was used to characterize the temporal pattern of sensitiza-
tion and its predictors during ventricular assist device support. To account for
nonrandom factors in device selection when comparing HeartMate (Thermo Car-
diosystems, Inc, Woburn, Mass) and Novacor (Baxter Healthcare Corp, Novacor
Div, Oakland, Calif) devices, we propensity-matched patients according to baseline
characteristics.
Results: T-cell panel reactive antibody increased rapidly after implantation of the
ventricular assist device and then immediately began to decrease. Predictors of
higher T-cell panel reactive antibody during support with the assist device were a
shorter interval from device implantation to T-cell panel reactive antibody mea-
surement (P .0001), female sex (P .0004), younger age (P .01), higher T-cell
panel reactive antibody before device implantation (P  .03), more perioperative
red blood cell transfusions (P  .006), and an earlier date of device implantation (P
 .001). In matched patients, device type was not a predictor of higher T-cell panel
reactive antibody during ventricular assist device support (P  .8).
Conclusions: HLA sensitization during ventricular assist device support is not
constant but increases rapidly at implantation and then decreases. This temporal
pattern of sensitization is influenced by patient factors and not by the type of device.
Antibodies to class I human leukocyte antigens (HLA sensitization)in heart transplant recipients are associated with graft rejectionand decreased transplant survival.1 Studies of immunologicchanges in patients requiring an implantable ventricular assistdevice (VAD) who received the HeartMate device (Thermo Car-diosystems, Inc, Woburn, Mass) suggest that excessive antibody
production during VAD support may be related to the VAD blood-contacting
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biomaterial.2-4 In this context, it is not clear whether there
are differences among currently available devices (and their
different biomaterials) in contributing to HLA sensitization.
Other studies of HLA sensitization during VAD support
suggest that transfusions and sensitization before device
implantation (especially in women) are important risk fac-
tors.5,6 At our institution, we have had substantial experi-
ence with both HeartMate and Novacor (Baxter Healthcare
Corp, Novacor Div, Oakland, Calif) implantable VADs.
The purposes of this study were to (1) characterize the
temporal pattern of T-cell panel reactive antibody (TPRA)
during VAD support, (2) identify predictors of higher
TPRA during VAD support, and (3) determine whether
device type remained a predictor after accounting for non-
random device selection.
Methods
Patients
Between December 1991 and August 2000, 239 patients received
implantable VADs at The Cleveland Clinic Foundation as a bridge
to transplantation (n  236) or as permanent therapy (n  3).
Patients were included regardless of pretransplantation manage-
ment. Thirty patients (13%) received plasmapheresis and myco-
phenolate mofetil before transplantation. None received cyclo-
phosphamide or intravenous immunoglobulin. Patients without
sensitization data (n  5) and individual recipients who had
multiple device types used (n 3) were not included in this study,
leaving 231 patients. Of these, 37 (16%) were female, and 141
(61%) had ischemic cardiomyopathy as the cause of end-stage
heart failure. The duration of VAD support ranged from 0 to 1043
days, with 18,200 cumulative patient-days of support.
Device types used (Table 1) included HeartMate only (n 
166), Novacor only (n 55), and Thoratec (Thoratec Corporation,
Pleasanton, Calif) only (n  10: 4 recipients with isolated left
VADs, 1 with an isolated right VAD, and 5 with biventricular
VADs). Of the 231 patients, 154 received a heart transplant, 3 were
explanted for recovery, 68 died on support, and 6 were on VAD
support as of the study closure date.
Measurement of HLA Sensitization
Recipients’ sera were heat-treated to remove immunoglobulin M
TABLE 1. Devices used, by type and year
Device
Year o
1992* 1993 1994 1995
HeartMate 9 15 13 32
Novacor 0 0 0 0
Thoratec 0 0 0 0
Total 9 15 13 32
VAD, Ventricular assist device.
*Includes December 1991.
†Up to August 2000.reactivity and were tested by complement-dependent lymphocyto-
The Journal of Thoracictoxicity against a comprehensive 25- to 50-member cell panel of
HLA-typed donors selected to represent most of the defined HLA
specificities. Using cytotoxicity by standard dye-exclusion assay,
positive reactions were expressed quantitatively as a percentage of
the total T-cell panel.
TPRA was measured before VAD implantation (median, 3
days; 10th percentile, 1 day; 90th percentile, 82 days), approxi-
mately 2 weeks after VAD implantation, irregularly thereafter
depending on clinical events and length of support, and at trans-
plantation. A total of 593 TPRA measurements were obtained for
the 231 patients: 224 (97%) had a TPRA measurement before
VAD implantation, 106 (54% of those alive at 2 weeks) had a
measurement approximately 2 weeks after VAD implantation, and
150 (97% of those who underwent transplantation) had a measure-
ment at transplantation; the remaining measurements were per-
formed between approximately 2 weeks and transplantation. Au-
toantibodies were found in 2 patients (0.9%).
Data Analysis
The end point for this study was TPRA level during VAD support.
The analytic strategy was as follows: (1) determine the temporal
pattern of TPRA change during VAD support; (2) identify mod-
ulators of the pattern, particularly the effect of VAD type; and (3)
verify the presence or absence of an effect of VAD type by
accounting for nonrandom device selection.
Specific Methods
The temporal pattern of TPRA levels during VAD support was
characterized by using longitudinal mixed modeling (PROC
MIXED; SAS Inc, Cary, NC) to account for (1) the variable
intervals of TPRA measurements during VAD support and (2)
repeated (serial) measurements in each patient.7 Because of the
limited provision within the software for exploring multivariable
relations, we screened variables by using ordinary multivariable
linear regression (which assumes independence of observations) to
identify candidates for mixed-model investigation; these candi-
dates and transformations of continuous and ordinal variables were
entered simultaneously into the mixed model and were then elim-
inated sequentially until all variables remaining had a P value of .1
or less. Nearly all TPRA measurements were obtained within the
first 7 months of VAD support; therefore, values in “naturally
selected” patients who required prolonged VAD support obtained
D placement
Total96 1997 1998 1999 2000†
0 3 9 43 12 166
2 35 17 1 0 55
0 0 5 1 4 10
2 38 31 45 16 231f VA
19
3
3beyond 7 months (15 of 593 measurements) were not analyzed.
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particularly of the type of device, were identified by using the
model for the TPRA pattern combined with the variables listed in
Appendix 1. Specifically, this required examining the interactions
of each variable with the time of TPRA measurement. In screening
variables, we found that plasmapheresis had been used exclusively
in patients with high TPRA. Therefore, we did not use it in the
analysis.
To account for nonrandom factors in device selection when
comparing HeartMate and Novacor devices, we propensity-
matched patients according to baseline characteristics (Appendix
2) and compared TPRA patterns.8,9
Presentation
Descriptive statistics are summarized as mean and SD for contin-
uous variables when they were approximately normally distributed
and as median, 25th, and 75th percentile and range when they were
not. Categorical variables are expressed in frequencies and per-
centages.
Nomograms from the analyses are presented in which values
for specific variables, such as age and TPRA before VAD implan-
tation, were entered into the regression equations and the equations
solved. The results are presented graphically with confidence lim-
its equivalent to 1 SE (68%).
Results
Temporal Pattern of HLA Sensitization During VAD
Support
TPRA during VAD support increased immediately after
VAD implantation and then rapidly began to decrease (P 
.0001) to levels generally lower than before placement
(Figure 1). Mean TPRA before VAD implantation was
4.0%. Mean TPRA at 1 day, 2 weeks, 1 month, 3 months, 5
months, and 7 months after VAD implantation was 6.4%,
Figure 1. Mean TPRA after VAD implantation versus time after
VAD implantation. Solid line is the mean curve generated by
longitudinal data analysis, and dashed lines are confidence limits
equivalent to 1 SE (68%).3.0%, 2.4%, 1.6%, 1.3%, and 1.2%, respectively.
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Modulators of the temporal pattern of TPRA during VAD
support were female sex (P  .0004), younger age (P 
.01), higher TPRA before VAD implantation (P  .03),
more perioperative red blood cell transfusions (P  .006),
and earlier date of VAD implantation (P  .001; Table 2).
It is important to note that device type (HeartMate vs
Novacor vs Thoratec) was not identified as a modulator of
TPRA level (P  .7), nor were baseline characteristics
related to severity of illness.
The strong effect of female sex on TPRA is demon-
strated in Figure 2. The effect of younger age on higher
TPRA 2 weeks after VAD implantation is illustrated in
Figure 3. The modest relationship of TPRA level before and
2 weeks after VAD implantation is illustrated in Figure 4.
The strong effect of increasing the number of perioperative
units of red blood cell transfusions on TPRA 2 weeks after
VAD implantation is illustrated in Figure 5.
Matched Comparison of Device Types
Patients who received HeartMate and Novacor devices dif-
fered in age, creatinine level, bilirubin level, and TPRA
before VAD implantation (Table 3). After propensity
matching, the resulting pairs were well matched (Table 4).
In matched patients, device type was not a predictor of
TABLE 2. Predictors of higher TPRA measurements during
VAD support
Risk factor Coefficient  SE P value
Women 1.14 0.28 .0001
Younger age* 1.5 0.44 .0008
Shorter interval from VAD
implantation to TPRA
measurement†
0.70 0.17 .0001
Interaction between age and
interval from VAD
implantation to TPRA
measurement‡
0.46 0.15 .003
Higher TPRA before VAD
implantation
0.022 0.010 .03
More perioperative red
blood cell transfusions§
0.37 0.13 .004
Earlier date of VAD
implantation
0.016 0.0045 .0006
Novacor¶ 0.093 0.22 .7
Thoratec¶ 0.088 0.58 .9
TPRA, T-cell panel reactive antibody; VAD, ventricular assist device.
*[50/age (y)] inverse transformation.
†Ln[interval to TPRA measurement (years)] logarithmic transformation.
‡As age decreases, the influence of shorter interval becomes smaller.
§Ln(perioperative red blood cell transfusions) logarithmic transformation.
(Date of VAD implantation)2 squared transformation.
¶Versus HeartMate.higher TPRA level during VAD support (P  .8; Table 5).
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TPRA Measurement
Traditionally, TPRA results are expressed as greater than
or less than 10% positive reactions. In this study, to use
all available information, we analyzed TPRA as a con-
tinuous value from 0% to 100%. The relations found with
this analytic technique support this approach. In addition,
because TPRA measurements are not continuously mon-
itored but are made at different times for different pa-
tients, and at variable times for an individual patient,
determining the time after VAD implantation at which a
patient’s TPRA exceeds 10% is not possible with any
Figure 2. Risk-adjusted relation of TPRA after VAD implantation
and time by sex. This is a nomogram of Table 2, in which age 
55 years (median age), TPRA before VAD implantation  0,
perioperative red blood cell transfusions 12 units (median), and
date of VAD implantation  1997.
Figure 3. Risk-adjusted relation of TPRA and age 2 weeks and 3
months after VAD implantation. This nomogram of Table 2 is for a
woman; TPRA before VAD implantation  0, perioperative red
blood cell transfusions  12 units (the median), and date of VAD
implantation  1997 (the median date).degree of accuracy.
The Journal of ThoracicPrincipal Findings
Temporal pattern of sensitization. The temporal pat-
terns of TPRA change during VAD support consisted of a
rapid increase followed by a rapid progressive decrease.
This pattern suggests greater effects of early postoperative
events rather than a continued effect of VAD support. This
may be explained by any or all of the following: (1) HLA in
transfusions administered early after surgery; (2) initial in-
teraction between blood and the device surface (contact
activation), ameliorated rapidly by passivation of the sur-
face by serum proteins deposited on it10-12; (3) longer-term
remodeling of the device blood-contacting surface by
pseudointima formation, making it less immunogenic with
Figure 5. Risk-adjusted relation of TPRA 2 weeks after VAD
implantation and number of perioperative red blood cell transfu-
sions. This is a nomogram of Table 2 for a woman; age 55 years
(median), TPRA before VAD implantation  0, and date of VAD
implantation  1997.
Figure 4. Risk-adjusted relation of TPRA before and 2 weeks after
VAD implantation. This nomogram of Table 2 is for a woman, age
 55 years (median), perioperative red blood cell transfusions 
12 units, and date of VAD implantation  1997.longer device support; and (4) alteration of the systemic
and Cardiovascular Surgery ● Volume 127, Number 6 1803
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of preoperative shock.
Predictors of sensitization. Predictors of higher TPRA
level during VAD support underscore the importance of the
patient profile and events during support. Consistent with
previous reports, we found women to be at higher risk.5
Although data were not available on the number of previous
pregnancies, past heart transplant investigations have found
increased risk associated with being a woman was a surro-
gate for previous pregnancies.13 Younger age suggests that
enhanced immune responsiveness is a component of sensi-
tization. Total red blood cell transfusions were an important
predictor of higher TPRA, which is also consistent with the
report of Massad and colleagues.5 This might be related to
the HLA found on leukocytes within the transfusions and to
associated events, such as shock. Although the leukocyte-
reduced fraction of red blood cell transfusions was not
TABLE 3. Characteristics of unmatched HeartMate and No
Characteristic HeartMate (n
Demographics
Age (mean years  SD) 55 
Women (%) 24 (14)
Clinical history
Bilirubin, median (Q1, Q3) 1.4 (0.9,
Creatinine, median (Q1, Q3) 1.5 (1.1,
Pre-VAD TPRA, median (Q1, Q3) 0 (0, 4
Intubation (%) 102 (61)
IABP (%) 127 (77)
Previous cardiac surgery (%) 84 (51)
Idiopathic etiology (%) 46 (28)
Ischemic etiology (%) 102 (61)
ECMO (%) 38 (23)
Q1, 25th percentile; Q3, 75th percentile; TPRA, T-cell panel reactive a
oxygenation; VAD, ventricular assist device.
TABLE 4. Characteristics of matched HeartMate and Nova
Characteristic HeartMate (
Demographics
Age (mean years  SD) 53 
Women (%) 6 (12)
Clinical history
Bilirubin, median (Q1, Q3) 1.6 (1.1,
Creatinine, median (Q1, Q3) 1.6 (1.2,
Pre-VAD TPRA, median (Q1, Q3) 0 (0, 0)
Intubation (%) 34 (68)
IABP (%) 42 (84)
Previous cardiac surgery (%) 27 (54)
Idiopathic etiology (%) 13 (26)
Ischemic etiology (%) 35 (70)
ECMO (%) 10 (20)
Q1, 25th percentile; Q3, 75th percentile; TPRA, T-cell panel reactive a
oxygenation; VAD, ventricular assist device.associated with decreased sensitization, we have used leu-
1804 The Journal of Thoracic and Cardiovascular Surgery ● Junkocyte-reduced products since 1995 on the basis of earlier
studies that showed the benefits of this strategy.14 Platelet
transfusions have been found in earlier studies to be predic-
tors of sensitization, especially non–leukocyte-reduced
platelets,5,6,14 but we did not observe this. We attribute
much of the decrease in sensitization over the experience to
changes in blood transfusion methods (such as use of leu-
kocyte-depleted products) and to the use of blood-sparing
techniques (such as the routine use of aprotinin and vitamin
K). The role of pretransplantation plasmapheresis could not
be determined in this study because only highly sensitized
patients received this treatment.
Role of device. In this study, device type (HeartMate vs
Novacor vs Thoratec) was not a predictor of sensitization
either in the initial analysis or in propensity-matched pairs
of HeartMate and Novacor patients. Decisions regarding
device type were related to device properties (reliability and
r recipients
66) Novacor (n  55) P value
52  12 .1
7 (13) .7
1.6 (1.3, 2.3) .01
1.5 (1.3, 2.1) .07
0 (0, 1.5) .6
32 (58) .6
45 (81) .4
28 (51) .9
18 (33) .5
35 (63) .7
8 (15) .18
dy; IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane
recipients
0) Novacor (n  50) P value
54  10 .6
5 (10) .7
1.6 (1.2, 2.5) .9
1.5 (1.3, 2.0) .7
0 (0, 1) .7
30 (60) .4
41 (82) .8
26 (52) .8
15 (30) .6
33 (66) .7
8 (16) .6
dy; IABP, intra-aortic balloon pump; ECMO, extracorporeal membranevaco
 1
10
2.6)
2.1)
)
ntibocor
n  5
12
2.6)
2.4)
ntibothromboembolism) and not to the potential for sensitization.
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have focused on interactions with HeartMate devices. Initial
implantation is associated with activation of complement
and coagulation factors, and this contributes to bleeding
after implantation.15-18 However, the textured surface of the
HeartMate device allows formation of a pseudointima after
implantation.19,20 At explantation, the pseudointima con-
tains macrophages and T cells.21,22 Previous studies using
an in vitro model containing VAD pseudointima and bio-
material have found T-cell activation with subsequent apo-
ptosis and B-cell activation.3 This phenomenon has recently
been shown to peak shortly after VAD implantation and to
decrease over time in patients receiving a DeBakey VAD
(MicroMed Technologies, Inc, Houston, Tex).23
In combination, the pattern and predictors of sensitiza-
tion suggest that the relevant influences are sensitization
before VAD placement (multiparous women and previous
transfusions), immune responsiveness (age), and amount of
HLA exposure (transfusions). Our findings suggest that
device biomaterial/immune system interactions are tran-
sient, not constant, and they occur contemporaneously with
other influences. The differences in the HeartMate and
Novacor devices, including their respective biomaterials,
have not resulted in detectable differences in HLA sensiti-
zation between the 2.
Future Horizons
Newer, smaller VADs (eg, axial flow devices) may offer
easier implantation with less perioperative bleeding, result-
ing in fewer perioperative transfusions and a smaller surface
area for immunologic exposure. Immunosuppression begun
early after VAD implantation may be effective in decreas-
ing antibody production.
Limitations
This was an observational study encompassing the entire
VAD experience at our institution. Selection of device type
changed nonsystematically over time. After the 2-week time
point, TPRA data were obtained at variable intervals influ-
enced by clinical events and length of device support. Al-
though our analysis accounted for this variation, it did not
account for so-called informative censoring—in this case,
depletion of the study group by nonrandom selection of
patients for transplantation. Finally, the patient population is
a complex, heterogeneous group, and there have been many
incremental practice changes over time. Some of these
factors, including preferential use of plasmapheresis in
highly sensitized patients, are surely not accounted for and
could individually correlate with the end points of HLA
sensitization (confounding).
Conclusions
The pattern and predictors of sensitization suggest that the
relevant influences are sensitization before VAD implanta-
The Journal of Thoraciction (multiparous women and previous transfusions), im-
mune responsiveness (age), amount of HLA exposure
(transfusions), and initial interaction between blood and the
contact surface. Our findings suggest that device biomate-
rial/immune system interactions may not be constant and
occur in combination with other influences. The potential
differences in the devices (and their respective biomaterials)
have not resulted in detectable differences in HLA sensiti-
zation between HeartMate and Novacor devices.
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The influence of device type (HeartMate vs Novacor) on TPRA
serial measurements was determined for all 221 patients and for
propensity-matched pairs. In the entire group, HeartMate made up
166 (75%) and Novacor 55 (25%) of the devices.
As a first step toward propensity analysis, a parsimonious
model was established for Novacor by using multivariable logistic
Appendix 1. Variables used in analysis
VAD type
Age
Sex
Cause of heart failure (ischemic, dilated, valvar, congenital,
myocarditic)
Previous cardiac surgery
Preoperative creatinine
Preoperative bilirubin
Preoperative intubation
Preoperative hemodialysis
Preoperative IABP
Preoperative ECMO
Preoperative Abiomed BVS 5000 support
Pre-VAD placement TPRA
Need for any mechanical right ventricular support (ECMO,
Abiomed BVS 5000, and/or Thoratec RVAD)
Transfusions (perioperative [1 day of VAD implantation] and
total)
Red blood cells (total units, leukocyte-reduced units)
Platelets (total units, leukocyte-reduced units)
Fresh frozen plasma (total units)
Bloodstream infection (number of episodes)
VAD, Ventricular assist device; IABP, intra-aortic balloon pump; ECMO,
extracorporeal membrane oxygenation; RVAD, right ventricular assist de-
vice; TPRA, T-cell panel reactive antibody.
Appendix TABLE 1. Predictors of Novacor versus Heart-
Mate
Predictor Logistic coefficient  SE P value
Younger age* 0.93 0.48 .05
Lower pre-VAD TPRA 0.066 0.038 .08
Higher creatinine† 0.74 0.41 .07
Higher bilirubin‡ 3.4 1.1 .002
Lower bilirubin§ 2.5 0.88 .004
VAD, Ventricular assist device; TPRA, T-cell panel reactive antibody.
*[50/age (y)] inverse transformation.
†(1.5/creatinine) inverse transformation.
‡(1.4/bilirubin) inverse transformation.
§Ln(bilirubin) logarithmic transformation.e 2004
Kumpati et al Cardiothoracic Transplantationregression.8 All pre-VAD variables were considered (Appendix
Table 1) for determining factors associated with group member-
ship (Novacor vs HeartMate). Continuous variables were initially
analyzed by decile analysis; we then selected those transformations
of scale that best calibrated the variable to group membership.
Having established a parsimonious model, we added all other
pre-VAD variables representing patient sex and clinical history
(saturated model). These included female sex, idiopathic etiology,The Journal of Thoraciction, intra-aortic balloon pump, and previous cardiac surgery. The
c statistic was 0.76.
A propensity score was calculated for each patient by solving
the saturated model for the probability of a Novacor device being
implanted.24 Greedy matching using the propensity score as the
sole criterion yielded 50 well-matched pairs.25 Multivariable lon-
gitudinal mixed modeling was again performed of TPRA measure-
ments by using these 50 pairs of patients and forcing in deviceTXischemic etiology, extracorporeal membrane oxygenation, intuba- type.and Cardiovascular Surgery ● Volume 127, Number 6 1807
